Assessment of disease activity and damage in SLE: Are we there yet?
- 2 December 2023
- journal article
- research article
- Published by Elsevier in Best Practice & Research Clinical Rheumatology
- Vol. 37 (4) , 101896
Abstract
No abstract availableKeywords
This publication has 110 references indexed in Scilit:
- Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trialsAnnals of the Rheumatic Diseases, 2012
- Development of the CLASI as a Tool to Measure Disease Severity and Responsiveness to Therapy in Cutaneous Lupus ErythematosusArchives of Dermatology, 2011
- Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trialThe Lancet, 2011
- Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI): a modified outcome instrument for cutaneous lupus erythematosusBritish Journal of Dermatology, 2010
- Novel evidence‐based systemic lupus erythematosus responder indexArthritis Care & Research, 2009
- British isles lupus assessment group 2004 index is valid for assessment of disease activity in systemic lupus erythematosusArthritis & Rheumatism, 2007
- Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO)Kidney International, 2005
- Systemic lupus erythematosus in three ethnic groups. XX. Damage as a predictor of further damageRheumatology, 2003
- The development and initial validation of the systemic lupus international collaborating clinics/American college of rheumatology damage index for systemic lupus erythematosusArthritis & Rheumatism, 1996
- Derivation of the sledai. A disease activity index for lupus patientsArthritis & Rheumatism, 1992